The headache-inducing effect of cilostazol in human volunteers

Cephalalgia

Volumn 26, Issue 11, 2006, Pages 1304-1309

  Birk, S ^a   Kruuse, C ^a   Petersen, K A ^a   Tfelt Hansen, P ^a   Olesen, J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

cAMP; Cilostazol; Migraine; Phosphodiesterase type 3

Indexed keywords

CILOSTAZOL; CYCLIC AMP; GLYCERYL TRINITRATE; PLACEBO;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; FLUSHING; HEART PALPITATION; HEAT SENSATION; HUMAN; MALE; MEDICAL SOCIETY; MIGRAINE WITHOUT AURA; NAUSEA; NORMAL HUMAN; PAIN THRESHOLD; PATHOGENESIS; PHONOPHOBIA; PHOTOPHOBIA; PROTEIN DEGRADATION; RATING SCALE; SCORING SYSTEM; SIDE EFFECT; VASCULAR HEADACHE;

ADULT; AREA UNDER CURVE; CROSS-OVER STUDIES; CYCLIC AMP; DOUBLE-BLIND METHOD; FEMALE; HEADACHE; HUMANS; MALE; PAIN MEASUREMENT; PLACEBOS; TETRAZOLES; VASODILATOR AGENTS;

EID: 33745913851     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2006.01218.x     Document Type: Article

References (34)

1. Lassen LH, Ashina M, Christiansen I, Ulrich V, Grover R, Donaldson J et al. Nitric oxide synthase inhibition: a new principle in the treatment of migraine attacks. Cephalalgia 1998; 18:27-32.
2. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002; 22:54-61.
3. Thomsen LL, Olesen J. Nitric oxide in primary headaches. Curr Opin Neurol 2001; 14:315-21.
4. Kruuse C, Thomsen LL, Birk S, Olesen J. Migraine can be induced by sildenafil without changes in middle cerebral artery diameter. Brain 2003; 126:241-7.
5. Kruuse C, Thomsen LL, Jacobsen TB, Olesen J. The phosphodiesterase 5 inhibitor sildenafil has no effect on cerebral blood flow or blood velocity, but nevertheless induces headache in healthy subjects. J Cereb Blood Flow Metab 2002; 22:1124-31.
6. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004; 350:1104-10.
7. Poyner DR, Sexton PM, Marshall I, Smith DM, Quirion R, Born W et al. International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors. Pharmacol Rev 2002; 54:233-46.
8. Jansen-Olesen I, Mortensen A, Edvinsson L. Calcitonin gene-related peptide is released from capsaicin-sensitive nerve fibres and induces vasodilatation of human cerebral arteries concomitant with activation of adenylyl cyclase. Cephalalgia 1996; 16:310-6.
9. Schror K. The pharmacology of cilostazol. Diabetes Obes Metab 2002; 4 (Suppl. 2):S14-9.
10. Birk S, Edvinsson L, Olesen J, Kruuse C. Analysis of the effects of phosphodiesterase type 3 and 4 inhibitors in cerebral arteries. Eur J Pharmacol 2004; 489:93-100.
11. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004; 24:1352-8.
12. Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet 1999; 37:13-23.
13. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989; 38:17-24.
14. Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain 2000; 123:1703-9.
15. The international classification of headache disorders. Cephalalgia 2004; 24:1-160.
16. Pratt CM. Analysis of the cilostazol safety database. Am J Cardiol 2001; 87:28D-33D.
17. Bramer SL, Forbes WP, Mallikaarjun S. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease. Clin Pharmacokinet 1999; 37:1-11.
18. Thomsen LL, Iversen HK, Brinck TA, Olesen J. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 1993; 13:395-9.
19. Olesen J, Iversen HK, Thomsen LL. Nitric oxide super-sensitivity: a possible molecular mechanism of migraine pain. Neuroreport 1993; 4:1027-30.
20. Iversen HK, Holm S, Friberg L. Intracranial hemodynamics during intravenous nitroglycerin infusion. Cephalalgia 1989; 9:84-5.
21. Lassen LH, Christiansen I, Iversen HK, Jansen-Olesen I, Olesen J. The effect of nitric oxide synthase inhibition on histamine induced headache and arterial dilatation in migraineurs in press. Cephalalgia 2003; 23:877-86.
22. Petersen KA, Lassen LH, Birk S, Lesko L, Olesen J. BIBN4096BS antagonizes human alpha-calcitonin gene related peptide-induced headache and extracerebral artery dilatation. Clin Pharmacol Ther 2005; 77:202-13.
23. Nichols FTd, Mawad M, Mohr JP, Stein B, Hilal S, Michelsen WJ. Focal headache during balloon inflation in the internal carotid and middle cerebral arteries. Stroke 1990; 21:555-9.
24. Thomsen LL, Olesen J. Nitric oxide theory of migraine. Clin Neurosci 1998; 5:28-33.
25. Bendtsen L. Sensitization: Its role in primary headache. Curr Opin Investig Drugs 2002; 3:449-53.
26. Levy D, Strassman AM. Distinct sensitizing effects of the cAMP-PKA second messenger cascade on rat dural mechanonociceptors. J Physiol 2002; 538:483-93.
27. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH. An association between migraine and cutaneous allodynia. Ann Neurol 2000; 47:614-24.
28. Degerman E, Belfrage P, Manganiello VC. Structure, localization, and regulation of cGMP-inhibited phosphodiesterase (PDE3). J Biol Chem 1997; 272:6823-6.
29. Sudo T, Tachibana K, Toga K, Tochizawa S, Inoue Y, Kimura Y et al. Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity. Biochem Pharmacol 2000; 59:347-56.
30. Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2000; 36:351-60.
31. Zanferrari C, Razumovsky AY, Lavados PM, Sen S, Oppenheimer SM. Effect of adenosine on cerebral blood flow velocity. J Neuroimaging 2001; 11:272-9.
32. Kruuse C, Jacobsen TB, Lassen LH, Thomsen LL, Hasselbalch SG, Dige-Petersen H et al. Dipyridamole dilates large cerebral arteries concomitant to headache induction in healthy subjects. J Cereb Blood Flow Metab 2000; 20:1372-9.
33. Birk S, Petersen KA, Kruuse C, Guieu R, Jonassen O, Eisert W et al. The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. Cephalalgia 2005; 25:369-77.
34. Goadsby PJ. New targets in the acute treatment of headache. Curr Opin Neurol 2005; 18:283-8.